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Abstract
Background: Interpretation of mediastinal biopsy is often challenging even for experienced pathologists especially
when a hematolymphoid neoplasm is suspected. Primary mediastinal large B-cell lymphoma (PMLBCL) and classic
Hodgkin lymphoma (CHL) represent two major types of mature B-cell lymphomas of the mediastinum. Although
PMLBCL and mediastinal CHL share many clinicopathologic characteristics, their treatment strategies and responses
are remarkably different. We therefore aimed to find distinctive histologic or protein markers to better differentiate
these two lesions.
Methods: Search for primary mediastinal B-cell lymphomas found 52 consecutive cases from 3 university hospitals
of Korea during 2005 to 2012. Among them, 32 cases that were available for additional immunohistochemistry (IHC)
assessment were enrolled in this study. These cases consisted of the following: CHL (N = 13), PMLBCL (N = 16), and
B-cell lymphoma unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL (gray
zone lymphoma, N = 3). Along with the clinicopathologic findings, the expression of p63, GATA3 and cyclin E was
investigated by IHC in the three categorized lesions mentioned above.
Results: Most clinical features overlapped between PMLBCL and CHL except for the increased disease progression
and mortality found in PMLBCL. In the pathologic review, the presence of epithelioid granuloma favored a
diagnosis of CHL, whereas reticulated or alveolar patterns of fibrosis were characteristic of PMLBCL. For protein
markers, p63 was predominantly positive in PMLBCL (15/16) compared with CHL (2/13), which indicates that p63 is
a marker of the highest diagnostic accuracy when calculated by the area under the ROC curve. GATA3 was
expressed in the majority of CHL cases (10/13) compared with PMLBCL (0/16), while the expression of cyclin E was
only rarely present in a minor population of PMLBCL.
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Conclusions: P63 expression in tumor cells, even focal expression, and no GATA3 is the most helpful feature in
distinguishing PMLBCL from mediastinal CHL.
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Background
Malignant lymphoma is one of the most common causes
of bulky anterior mediastinal masses in young patients
[1]. Lymphomas of the mediastinum can originate either
from the thymus or the lymph nodes, and thymic
lymphomas show unique pathologic characteristics dis-
tinct from common nodal lymphomas [2]. Two primary
representative T- and B-cell lymphomas arise in the thy-
mus: precursor T-lymphoblastic lymphoma/leukemia
(T-LBL) and primary mediastinal large B-cell lymphoma
(PMLBCL). In T-LBL, prompt pathologic diagnosis is
critical because the tumor cells are highly proliferative
and frequently give rise to acute airway compression.
However, T-LBL can be relatively easily excluded be-
cause of its uniform histologic features and by confirm-
ation of the pathognomonic marker TdT by
immunohistochemistry (IHC). On the contrary, the dif-
ferential diagnosis of B-cell lymphomas is much more
complicated. PMLBCL and classic Hodgkin lymphoma
(CHL) constitute two major lymphomas of mediastinal
B-cell origin, although other types of B-cell lymphomas
such as marginal zone lymphoma do occur at a low inci-
dence. PMLBCL and CHL share a considerable degree
of similarity in terms of histomorphology, immunopro-
files and even gene expression patterns [3, 4]. The in-
trinsic nature of thymic B-cells and their
microenvironment are responsible for the clinicopatho-
logic features of these two lesions. Nevertheless, differ-
entiation of PMLBCL from CHL or other B-cell
lymphomas is crucial even in small specimens, because
they each have different therapeutic strategies [5] and
outcomes. However, histomorphologic features are fre-
quently obscured by crush artifacts, which are almost in-
evitable in mediastinal biopsy due to limitations of the
surgical approach. Therefore, recognition of the salient
histologic patterns and careful selection of protein
markers to minimize tissue loss should be pivotal in the
pathologic diagnosis. This study aimed to find histopath-
ologic parameters and immunohistochemical markers
that will best characterize PMLBCL and CHL.
Methods
Case selection
Cases of B-cell lymphomas arising in the mediastinum
from 2005 to 2012 were retrospectively reviewed from
the archives of three university hospitals in Korea. Cases
were selected when patients had solely mediastinal
masses without lymphadenopathy of the other sites or
when patients had a predominantly mediastinal presen-
tation if accompanied by other nodal lesions. Histopath-
ologic and immunohistochemical findings were reviewed
at a consensus meeting of five board-certified patholo-
gists (HJK, JEK, GSP, HKK, SKM) who agreed to use the
diagnostic criteria of the 2017 WHO classification tu-
mours of haematopoietic and lymphoid tissues [6]. Pa-
tients’ demographic data and other clinical
characteristics along with follow-up data were retrieved
from the electronic medical records.
Expression of protein markers and detection of EBV
Representative tissue sections that were 4 μm in thickness
were used for IHC and EBV-encoded RNA (EBER) in situ
hybridization (ISH). The primary antibodies used for rou-
tine pathologic examination are: CD3, CD5, CD10, CD15,
CD20, CD23, CD30, CD79a, BCL6, Pax5, and IRF4/
MUM-1. Additionally, IHC for GATA3 (Biocare Medical,
Concord, CA), p63 (Lab Vision, Fremont, CA) and cyclin
E (Santacruz Biotechnology, Santa Cruz, CA) was per-
formed to determine their usefulness in the differential
diagnosis. Expression of p63, GATA3 and cyclin E was
considered positive if the percentage of positive cells was
equal to or higher than 5%. To elucidate whether those
three proteins are site specific marker, 88 cases of non-
mediastinal DLBCL and 56 non-mediastinal CHL were in-
vestigated using tissue microarray blocks. All IHC and
EBER ISH assays were conducted using the Bench Mark
automated immunostainer (Ventana Medical Systems,
Tucson AZ) according to validated protocols.
Statistical analysis
Nonparametric Mann-Whitney U-test and Fisher’s Exact
Test were performed to compare IHC and EBER ISH re-
sults between each group of mediastinal B-cell lymph-
oma. Spearman’s rho was used to assess the correlation
between protein expression scores. Overall survival (OS)
was calculated from the date of diagnosis to the date of
death and was compared using univariable Kaplan-Meier
survival functions with log rank tests. The area under
the receiver operating characteristics curve tested by the
DeLong test was applied to determine the most discrim-
inative diagnostic marker [7]. The results were consid-
ered statistically significant if a two-tailed P-value was <
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0.05. All data were analyzed with SPSS software version
20.0 (SPSS Inc. IBM, NY, USA).
Results
Patient profile
Initially, 52 cases of mediastinal lymphomas of B-cell ori-
gin were reviewed and biopsy materials were obtained by
transthoracic needle biopsy (N = 32), video-assisted thora-
coscopic surgery (N = 12) or open surgical biopsy (N = 8).
Half of the needle biopsy specimens (16 of 32) were re-
moved from the study largely due to shortfall of samples
either by quality- or quantity-based standards, and 4 cases
of other type of B-cell lymphomas were also excluded be-
cause they were outside the scope of the study. Therefore,
32 cases were finally selected for this study: PMLBCL
(N = 16), CHL (N = 13), B-cell lymphoma, unclassifiable,
with features intermediate between DLBCL and classical
Hodgkin lymphoma (gray-zone lymphoma) (N = 3). The
detailed demographic data and survival plot of the patients
are shown in Table 1 and Fig. 1. Cases were predomin-
antly female, and the patients’ ages ranged from 15 to 86
years. Most PMLBCL patients were treated with
rituximab-based chemotherapy such as R-CHOP (rituxi-
mab, cyclophosphamide, doxorubicin, vincristine, and
prednisone) (13 of 16, 81.3%), while most CHL patients
(12 of 13, 92.3%) were managed by ABVD (doxorubicin,
bleomycin, vinblastine, and dacarbazine). Three patients
with gray zone lymphoma were treated with the R-CHOP
regimen because all had been previously diagnosed with
DLBCL; however, the diagnosis was revised to gray zone
lymphoma after review at the consensus meeting. The me-
dian follow-up was 72months (range 1–116months) for
CHL, and 13months (range 1–57months) for PMLBCL.
Cancer-specific death occurred in 5 patients, four of
whom were diagnosed with PMLBCL and one of whom
was diagnosed with gray zone lymphoma. Compared with
patients with CHL, patients with PMLBCL showed signifi-
cantly higher incidences of disease progression (p = 0.017)
and a tendency for shorter OS (p = 0.08) (Fig. 1).
Comparison of the pathologic features between PMLBCL
and CHL
The review of the pathological findings (Table 2, Figs. 2
and 3) revealed significant differences between PMLBCL
Table 1 Clinical profile of patients with B-cell lymphoma of the mediastinum
CHL, NS (N = 13) PMLBCL (N = 16) p value Gray zone (N = 3)
Age Median (Range) 26(15–73) 30 (19–51) 0.175 28 (25–52)
Sex Male: Female 4(30.8%): 9(69.2%) 6(37.5%): 10(62.5%) 1.000 2: 1
Methods of biopsy Needle: VATS: Open 6: 3: 4 10: 4: 2 0: 0: 3
IPI score High risk (> 3) or low 7(87.5%): 1(12.5%) 13(86.7%): 2(13.3%) 1.000 1: 2
Ann Arbor stage I-II: III-IV 8(80.0%): 2(20.0%) 10(71.4%): 4(28.5%) 1.000 1: 2
LDH Elevated or not 4(57.1%): 3(42.9%) 12(80.0%): 3(20.0%) 0.334 0: 3
ECOG score ≥2 or less 0: 12(100%) 0: 14(100%) 0: 3
Bone marrow Involved or not 1(9.1%): 10(90.9%) 2(13.3%): 13(86.7%) 1.000 0: 3
Bulky disease Yes or No 6(54.5%): 5(45.5%) 11(73.3%): 4(26.7%) 0.419 1: 2
B symptoms Yes or No 5(55.6%): 4(44.4%) 4(28.6%): 10(71.4%) 0.383 1: 2
Follow-up (months) Median (Range) 72 (1–116) 14(1–57) 48 (14–84)
Dead/Alive 0: 12(100%) 4(26.7%): 11(73.3%) 0.106 1: 2
Progression Yes or No 0: 12(100%) 6(42.9%): 8(57.1%) 0.017 1: 2
CHL classic Hodgkin lymphoma, NS nodular sclerosis, PMLBCL primary mediastinal diffuse large B-cell lymphoma (DLBCL); Gray, B-cell lymphoma unclassifiable, with
features intermediate between DLBCL and classic Hodgkin lymphoma; VATS video-assisted thoracoscopic surgery
Fig. 1 Overall survival of patients with primary mediastinal large B-
cell lymphoma and classic Hodgkin lymphoma
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and CHL with respect to the presence of compartmen-
talizing alveolar pattern fibrosis (0 vs. 75%), dense col-
lagenous bands (0 vs. 53%), diffuse sheet-like expression
of CD20 (0 vs 62.5%) and CD30 (100% vs 37.5%), and
positivity for CD23 (7.7% vs 37.5%), bcl-6 (0 vs 56.2%)
and IRF4/MUM1 (100% vs 50%), p63 (15.4% vs 93.8%)
and GATA3 (76.9% vs 0). Cyclin E was completely nega-
tive in all CHL cases, whereas a low frequency (two of
16 PMLBCL cases) of positive tumor cells was observed.
An inflammatory background including granuloma or
nodularity was not infrequently shared in the two dis-
ease groups. Among these pathologic parameters, ex-
pression of p63 or GATA3 and the presence of alveolar
fibrosis were found to be extremely sensitive and specific
markers for the differentiation of CHL from MLBCL
after calculating the area under the receiver operating
characteristics (Table 3). Additionally, expression of p63
and GATA3 were compared with non-mediastinal CHL
and DLBCL (Additional file 1: Table S1 and Add-
itional file 2: Table S2). GATA3 was preferentially
present in tumor cells of mediastinal CHL rather than
non-mediastinal origin (p = 0.000).
We performed the DeLong test to determine whether
the addition of several important pathologic variables
listed above could increase the diagnostic power for
CHL and PMLBCL, but p63 was demonstrated to be the
single most efficient marker of PMLBCL and was super-
ior to various combinations (Table 3).
Discussion
In this study, we evaluated the diagnostic efficacy of sev-
eral pathologic parameters including a few relatively un-
common markers in the two most representative
mediastinal B-cell lymphomas. As a result, alveolar or
compartmental fibrosis was the most specific and au-
thentic histologic feature supporting a PMLBCL diagno-
sis. Among the protein markers, p63 and GATA3 were
the most useful diagnostic markers; p63 was almost ex-
clusively present whereas GATA3 was completely nega-
tive in PMLBCL. However, because of the interpretation
difficulty of GATA3 based on the extremely low propor-
tion of positive tumor cells, the application of p63 IHC
is more highly recommended since it is easily
recognizable even in small biopsy materials.
Mediastinal CHL and PMLBCL are supposedly of the
same cellular origin, which has been supported by the
presence of common genetic alterations and gene ex-
pression profiles [3, 8, 9], and more recently by
immune-oncologic signatures such as PD-L1 or PD-L2
expression [10, 11]. The cellular origin of both tumors is
thought to be post-germinal center B-cells lacking sur-
face immunoglobulin,7 and almost all the Hodgkin/
Reed-Sternberg (HRS) cells of CHL and quite a few
tumor cells in PMLBCL express CD30. However, these
two lymphomas exhibit a spectrum of histopathologic
and immunophenotypic diversity based on the plasticity
of B-cells, which should undergo physiologic transform-
ation in the thymus. As is well known, tumor cells of
PMLBCL often reveal large atypical cells reminiscent of
HRS or even lacunar cells, therefore pathologists often
encounter diagnostic dilemmas. Our study demonstrated
that presence of fine reticulated or alveolar fibrosis
strongly favored PMLBCL, however, this pattern cannot
be easily recognizable in small biopsy materials. Substan-
tial efforts have been made to find a good immunohisto-
chemical marker of the mediastinal lymphomas, and
Table 2 Comparison of pathologic parameters
CHL, NS (N = 13) PMLBCL (N = 16) p value Gray
(N = 3)
Granuloma Present or absent 3(23.1%):10(76.9%) 0:16(100%) 0.078 0:3
Fibrosis Diffuse/nodular/reticular/none 8(61.5%):5(38.5%):0:0 1(6.2%):1(6.2%):12(75.0%):2(12.5%) < 0.001 1:2
CD20 Negative/focal/diffuse 11(84.6%):2(13.4%):0 0:6(37.5%):10(62.5%) < 0.001 0:3:0
CD23 Positive (> 30%) or negative 1(8.3%):11(91.7%)a 6(37.5%):10(62.5%) 0.024 2:1
CD30 Diffuse/ focal/negative 13(100%):0:0 6(37.5%):6(37.5%):4(25.0%) 0.001 2:1
IRF4/MUM1 Positive (> 30%) or negative 13(100%):0(0%) 8(50.0%):8(50.0%) 0.003 2:1
BCL6 Positive (> 30%) or negative 0:12(100%)a 9(56.2%):7(43.8%) 0.003 1:2
CD10 Positive (> 30%) or negative 0:12(100%)a 1(6.3%):15(93.7%) 1.000 0:3
COO GC or non-GCB 0:12(100%)a 6(37.5%):10(62.5%) 0.024 0:3
EBV Present or absent 1(7.7%):12(92.3%) 1(6.2%):15(93.8%) 1.000 0:3
P63 Positive (> 5%) or negative 2(15.4%):11(84.6%) 15(93.8%):1(6.2%) < 0.001 2:1
GATA3 Positive (> 5%) or negative 10(76.9%):3(23.1%) 0:16(100%) < 0.001 2:1
CyclinE Positive (> 5%) or negative 0:13(100%) 2(12.5%):14(87.5%) 0.492 0:3
CHL classic Hodgkin lymphoma, NS nodular sclerosis, PMLBCL primary mediastinal diffuse large B-cell lymphoma (DLBCL); Gray, B-cell lymphoma unclassifiable, with
features intermediate between DLBCL and classic Hodgkin lymphoma
a: immunohistochemistry for some antibodies was not done in one case due to exhaustion of stored tissues
Kim et al. Diagnostic Pathology          (2019) 14:133 Page 4 of 7
recently, p63, cyclin E and GATA3 [12–14] have
emerged as new diagnostic markers. P63 is one of the
best available markers of basal or myoepithelial differen-
tiation, but little is known of these proteins in hemato-
lymphoid tumors. Expression of p63 has been reported
in anaplastic large cell lymphoma [15], PMLBCL [16]
and gray zone lymphoma [11] but is almost uniformly
absent in CHL. In our series, p63 was demonstrated to
be the most specific marker of PMLBCL, whereas ex-
pression of GATA3, even in a single HRS-like cell sup-
ports a diagnosis of CHL. As in previous studies [11,
16], the frequency of either p63- or GATA3-positive
tumor cells in each case is variable but generally very
low. This is the practical reason why p63 is preferable to
GATA3 because of a relatively higher proportion of
positive tumor cells.
The molecular mechanisms of p63 expression in
PMLBCL and GATA3 expression in CHL have not been
clearly elucidated. Rearrangement or extra copies of the
TP63 gene were demonstrated in a subset of anaplastic
large cell lymphoma but not in PMLBCL. As a tumor
suppressor that is closely linked to the regulation of
proapoptotic activity by p53 in the germinal center, the
coordinative or reciprocal relationship between p63 and
B-cell signaling is unknown [17]. Likewise, the theoret-
ical background of GATA3 expression in CHL is also
uncertain. GATA3 is T-cell transcription factor required
for early T-cell development and its expression in B-cell
lymphoma including CHL is exceptional. Experimental
studies have revealed that deregulation of NFκB and
Notch-1 contributes to GATA3 expression in HRS cells,
which consequently leads to the activation of multiple
cytokines that control microenvironment of CHL [12].
Until now, no genetic alterations of GATA3 have been
reported, and its prognostic significance is not very high
in CHL. However, GATA3 positivity in even a few HRS-
like cells strongly supports the diagnosis of CHL in the
mediastinum, where GATA3 frequency is particularly
higher than other sites. Based on the heterogeneity of
GATA3 expression pattern, the aberrancy of GATA3 in
HRS more likely relies on microenvironmental factors
rather than genetic alteration.
We did not find p63, GATA3, or cyclin E to be helpful
for further characterizing gray zone lymphoma because
they showed intermediate pattern between CHL and
PMLBCL in our three cases. Our results are also in
agreement with the previous report performed by Eberle
et al. [11], which suggested the presence of common
immunophenotypic features and genetic alterations that
link gray zone lymphoma, CHL and PMLBCL and that
places gray zone lymphoma in a still ambiguous
category.
Fig. 2 Pathologic findings of primary mediastinal large B-cell lymphoma. Reticular fibrosis (a) or alveolar type tumor aggregates (b) is
characteristic. Expression of p63 (c), bcl-6 (d), and CD23 (e) were significantly higher than that of classic Hodgkin lymphoma. Minority of cases
showed focal positivity for cyclin E (F)
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As shown in this study, thymic B-cell neoplasms are pre-
dominantly large cell types, but other types of B-cell lymph-
oma can occur [18–22]. Thymic B cells represent only 0.3%
of total cellularity in the thymus, and the majority are ma-
ture B cells that would not undergo neoplastic transform-
ation. However, in certain conditions such as myasthenia
gravis or inflammation, migration of multipotent
hematopoietic cells leads to B-cell proliferation and germi-
nal center formation. In our series, two cases of CHL were
found to have concomitant thymic cysts. The emergence of
CHL in the preexisting thymic cysts has been reported. As
in previous studies, our cases also support the idea that the
pathogenesis of mediastinal CHL is associated with local-
ized inflammation resulting in B-cell hyperplasia. The de-
velopment of other types of B-cell lymphomas can be
explained with a similar background.
Conclusions
The distinction of mediastinal CHL and PMLBCL is critical
but challenging. We suggest that the presence of alveolar fi-
brosis and p63 expression strongly indicates PMLBCL,







AUC (95% CI) p value DeLong test (p value)
P63 84.6% 93.8% 91.7% 88.2% 0.892 (0.756, 1.000) < 0.001 reference
GATA3 75.0% 100.0% 100.0% 84.2% 0.875 (0.721, 1.000) 0.001 0.918
IRF4/MUM1 100.0% 50.0% 61.9% 100.0% 0.750 (0.570, 0.930) 0.023 0.133
BCL6 100.0% 56.2% 63.2% 100.0% 0.781 (0.609, 0.954) 0.012 0.276
CD30 100.0% 62.5% 68.4% 100.0% 0.813 (0.651, 0.974) 0.004 0.386
CD23 87.5% 71.4% 63.6% 90.9% 0.795 (0.595, 0.994) 0.024 0.745
EBV 92.3% 6.2% 44.4% 50.0% 0.493 (0.278, 0.708) 0.948
CyclinE 100.0% 12.5% 46.2% 100.0% 0.563 (0.348, 0.777) 0.577
Granuloma 23.1% 100.0% 100.0% 61.5% 0.615 (0.402, 0.828) 0.293
Alveolar fibrosis 100.0% 75.0% 76.5% 100.0% 0.875 (0.739, 1.000) 0.001 0.844
CHL classic Hodgkin lymphoma; NS, nodular sclerosis; PMLBCL; primary mediastinal diffuse large B-cell lymphoma; NPV negative predictive value; PPV positive
predictive value; AUC area under the receiver operating characteristics
Fig. 3 Classic Hodgkin lymphoma (a) showed significantly higher positivity for GATA3 (b). A case of gray zone lymphoma showed nodular
fibrosis (c), focal positivity for MUM1 (d), p63 (e) and negativity for GATA3 (f)
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whereas GATA3 positivity favors CHL even when GATA3
is expressed in a very low proportion of tumor cells.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13000-019-0918-x.
Additional file 1: Table S1. Expression of p63 and GATA3 between
mediastinal and non-mediastinal Hodgkin lymphoma.
Additional file 2: Table S2. Expression of p63 and GATA3 between
mediastinal and non-mediastinal B-cell lymphoma.
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